2289 completed, 724 recruiting, 707 terminated, 555 unknown. 5161 Phase 2, 1292 Phase 1, 169 Phase 3.
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-11-02 |
| Multi-CAR-T Cells Targeting B Cell Lymphomas 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 11 | 2027-06-01 | 2026-11-02 |
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma golcadomide, Obinutuzumab, Polatuzumab - Multi Center, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-04-29 | 2026-11-05 |
| Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | University of Washington | 27 | 2027-03-01 | 2026-11-02 |
| Teclistamab In Waldenstrom's Macroglobulinemia Teclistamab - Waldenstrom's Macroglobulinemia | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 24 | 2027-02-19 | 2026-09-01 |
| Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma Epcoritamab, Observation - Randomized, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-02-12 | 2026-11-02 |
| A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas Sacituzumab Tirumotecan (Sac-TMT) - Unresectable Thymic Carcinoma | Phase 2 | Not yet recruiting | National Cancer Center, Japan | 35 | 2027-02-01 | 2026-08-06 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL Treatment with blinatumomab given subcutaneously. - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | University of Alberta | 80 | 2027-01-02 | 2026-08-12 |
| Ceritinib Treatment for Recurrent Meningiomas Ceritinib - Recurrent Meningioma, Grade I and Grade II | Phase 2 | Not yet recruiting | Kevin Petrecca | 10 | 2027-01-01 | 2026-10-23 |
| CD34+ Transplants for Myeloid Malignancies Busulfan, Melphalan, Fludarabine - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | Phase 2 | Not yet recruiting | Guenther Koehne | 50 | 2027-01-01 | 2026-10-13 |
| Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization rhTPO prophylaxis plus EAP stem-cell mobilization - Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 70 | 2027-01-01 | 2026-09-30 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
Showing 20 of 5161. Sign in to see all of them.
Lymphoma (1276) · Lymphoma, Non-Hodgkin (1002) · Leukemia, Lymphocytic, Chronic, B-Cell (920) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (899) · Lymphoma, Large B-Cell, Diffuse (875) · Lymphoma, Follicular (719) · Leukemia (625) · Lymphoma, Mantle-Cell (604) · Hodgkin Disease (590) · Recurrence (445) · Leukemia, Myeloid, Acute (436) · Burkitt Lymphoma (419) · Lymphoma, B-Cell, Marginal Zone (393) · Multiple Myeloma (349) · Myelodysplastic Syndromes (346)
Hemic and Lymphatic Diseases (5160) · Immune System Diseases (4873) · Neoplasms by Histologic Type (4851) · Lymphoproliferative Disorders (4812) · Immunoproliferative Disorders (4798) · Neoplasms (4735) · Lymphoma (2362) · Hematologic Diseases (2234) · Lymphoma, Non-Hodgkin (1895) · Leukemia, Lymphoid (1742) · Pathological Conditions, Signs and Symptoms (1582) · Pathologic Processes (1550) · Disease Attributes (1435) · Leukemia (1358)
Rituximab (905) · Cyclophosphamide (838) · Vincristine (382) · Etoposide (353) · Doxorubicin (352) · Prednisone (318) · Cytarabine (313) · Methotrexate (286) · fludarabine (270) · fludarabine phosphate (262) · Dexamethasone (247) · Lenalidomide (245) · Filgrastim (240) · venetoclax (175) · Peripheral Blood Stem Cell Transplantation (164)
M.D. Anderson Cancer Center (288) · National Cancer Institute (NCI) (273) · Memorial Sloan Kettering Cancer Center (119) · Fred Hutchinson Cancer Center (102) · City of Hope Medical Center (70) · Dana-Farber Cancer Institute (53) · Novartis Pharmaceuticals (50) · Institute of Hematology & Blood Diseases Hospital, China (46) · Masonic Cancer Center, University of Minnesota (45) · Ruijin Hospital (45) · Alliance for Clinical Trials in Oncology (44) · Hoffmann-La Roche (43) · Sun Yat-sen University (43) · Mayo Clinic (41) · Fondazione Italiana Linfomi - ETS (40)
United States (3004) · China (736) · France (416) · Italy (406) · Germany (344) · United Kingdom (330) · Canada (309) · Spain (295) · Australia (230) · South Korea (189) · Belgium (180) · Poland (137) · Netherlands (133) · Japan (112) · Israel (101)
Elias Jabbour (13) · Ajay Gopal (12) · Craig Moskowitz, MD (11)
PMID 41671463, PMID 34515338, PMID 35622074, PMID 32499241, PMID 40135712, PMID 40550489, PMID 31401903, PMID 32632956, PMID 39319495, PMID 34393061, PMID 34398557, PMID 23524640, PMID 27209293, PMID 29358183, PMID 23065508, PMID 23834234, PMID 38502198, PMID 39563886, PMID 40802906, PMID 17242396, PMID 18035553, PMID 18424759, PMID 18557726, PMID 18596230, PMID 19066739, PMID 20236866, PMID 21403127, PMID 21502559, PMID 22430088, PMID 24443277, PMID 26182309, PMID 26373676, PMID 27282998, PMID 30125215, PMID 30620669, PMID 31050355, PMID 32770353, PMID 33242441, PMID 34048072, PMID 34608724, PMID 34780125, PMID 35007144, PMID 35787017, PMID 35882475, PMID 37981564, PMID 38551807, PMID 38662147, PMID 40156952, PMID 40472301, PMID 41843779
2023 (56), P30CA015704 (56), P30CA033572 (51), 2015 (41), U10CA180820 (40), 2018 (36), U10CA031946 (33), 2014 (30), 2016 (30), U10CA032102 (30), 2017 (29), P30CA016672 (29), P30CA015083 (27), U10CA180886 (27), 2009 (25)